Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matinas BioPharma Holdings Inc.

www.matinasbiopharma.com

Latest From Matinas BioPharma Holdings Inc.

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Deals Business Strategies

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing

Neglected Tropical Disease Designation Rejected For First Time By US FDA

Pneumocystis pneumonia was determined to not meet criteria for a neglected tropical disease that could win sponsors of a new treatment a priority review voucher; FDA made four other diseases eligible. 
Review Pathway Infectious Diseases

Pipeline Watch: Phase III Progress With Anacetrapib, ALKS 3831 And LentiGlobin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Matinas BioPharma Holdings Inc.
  • Senior Management
  • Jerome D Jabbour, Pres. & CEO
    Keith A Kucinski, CFO
    Raphael J Mannino, PhD, CSO
    Theresa Matkovits, PhD, Chief Development Officer
    James J Ferguson, MD, CMO
  • Contact Info
  • Matinas BioPharma Holdings Inc.
    Phone: (908) 443-1860
    1545 Route 206 S, Ste. 302
    Bedminster, NJ 07921
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register